IGC Pharma, Inc.IGCNYSE
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank77
5Y CAGR+9.7%
Year-over-Year Change
Year-over-year free cash flow growth rate
5Y CAGR
+9.7%/yr
Long-term compound
Percentile
P77
Within normal range
vs 5Y Ago
1.6x
Solid growth
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 41.72% |
| Q3 2025 | -38.59% |
| Q2 2025 | -70.65% |
| Q1 2025 | 33.33% |
| Q4 2024 | -44.21% |
| Q3 2024 | 50.50% |
| Q2 2024 | -121.27% |
| Q1 2024 | 49.16% |
| Q4 2023 | -0.06% |
| Q3 2023 | -10.36% |
| Q2 2023 | 23.90% |
| Q1 2023 | -15.01% |
| Q4 2022 | -9.07% |
| Q3 2022 | 32.54% |
| Q2 2022 | -63.47% |
| Q1 2022 | 41.72% |
| Q4 2021 | -5.28% |
| Q3 2021 | -20.61% |
| Q2 2021 | 25.84% |
| Q1 2021 | -28.56% |
| Q4 2020 | 26.29% |
| Q3 2020 | 44.15% |
| Q2 2020 | -82.55% |
| Q1 2020 | 30.55% |
| Q4 2019 | -58.53% |
| Q3 2019 | 39.07% |
| Q2 2019 | -249.35% |
| Q1 2019 | 15.03% |
| Q4 2018 | -320.46% |
| Q3 2018 | 40.21% |
| Q2 2018 | 52.70% |
| Q1 2018 | -222.10% |
| Q4 2017 | -235.16% |
| Q3 2017 | 79.65% |
| Q2 2017 | 43.53% |
| Q1 2017 | -1435.73% |
| Q4 2016 | 107.86% |
| Q3 2016 | -540.95% |
| Q2 2016 | 170.77% |
| Q1 2016 | -6501.22% |